JP2020518552A5 - - Google Patents

Download PDF

Info

Publication number
JP2020518552A5
JP2020518552A5 JP2019542485A JP2019542485A JP2020518552A5 JP 2020518552 A5 JP2020518552 A5 JP 2020518552A5 JP 2019542485 A JP2019542485 A JP 2019542485A JP 2019542485 A JP2019542485 A JP 2019542485A JP 2020518552 A5 JP2020518552 A5 JP 2020518552A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
subunit
multimeric
multimer
stranded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019542485A
Other languages
English (en)
Japanese (ja)
Other versions
JP7183167B2 (ja
JP2020518552A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/017062 external-priority patent/WO2018145086A1/en
Publication of JP2020518552A publication Critical patent/JP2020518552A/ja
Publication of JP2020518552A5 publication Critical patent/JP2020518552A5/ja
Application granted granted Critical
Publication of JP7183167B2 publication Critical patent/JP7183167B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019542485A 2017-02-06 2018-02-06 減少した腎クリアランスを有する多量体オリゴヌクレオチド Active JP7183167B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762455231P 2017-02-06 2017-02-06
US62/455,231 2017-02-06
US201762522363P 2017-06-20 2017-06-20
US62/522,363 2017-06-20
US201762561853P 2017-09-22 2017-09-22
US62/561,853 2017-09-22
PCT/US2018/017062 WO2018145086A1 (en) 2017-02-06 2018-02-06 Multimeric oligonucleotides having decreased kidney clearance

Publications (3)

Publication Number Publication Date
JP2020518552A JP2020518552A (ja) 2020-06-25
JP2020518552A5 true JP2020518552A5 (enExample) 2021-03-11
JP7183167B2 JP7183167B2 (ja) 2022-12-05

Family

ID=63039118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019542485A Active JP7183167B2 (ja) 2017-02-06 2018-02-06 減少した腎クリアランスを有する多量体オリゴヌクレオチド

Country Status (11)

Country Link
US (2) US11078484B2 (enExample)
EP (1) EP3576752A4 (enExample)
JP (1) JP7183167B2 (enExample)
KR (2) KR102623311B1 (enExample)
CN (1) CN110248665A (enExample)
AU (1) AU2018215684B2 (enExample)
CA (1) CA3051480A1 (enExample)
IL (2) IL267806B2 (enExample)
MX (1) MX2019009347A (enExample)
SG (1) SG11201906728TA (enExample)
WO (1) WO2018145086A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101141544B1 (ko) 2009-03-13 2012-05-03 한국과학기술원 에스아이알엔에이 다중 접합체 및 이의 제조방법
IL316159A (en) 2015-06-15 2024-12-01 Mpeg La Llc Defined Oligonucleotide Multimers and Methods for Manufacture Thereof
MX2019009347A (es) 2017-02-06 2019-10-07 Mpeg La Llc Oligonucleotidos multimericos con menor eliminacion en el riñon.
WO2020180897A1 (en) * 2019-03-04 2020-09-10 Mpeg La, L.L.C. Multimeric oligonucleotides with enhanced bioactivity
EP3946374A4 (en) * 2019-03-29 2023-07-19 University of Massachusetts OLIGONUCLEOTIDE-BASED MODULATION OF C9ORF72
EP3966328A4 (en) 2019-05-06 2023-10-18 University Of Massachusetts Anti-c9orf72 oligonucleotides and related methods
AU2020319911A1 (en) * 2019-07-30 2022-02-24 Mpeg La, L.L.C. Subcutaneous delivery of multimeric oligonucleotides with enhanced bioactivity
WO2021026476A1 (en) * 2019-08-08 2021-02-11 Mpeg La, L.L.C. Complement targeting with multimeric oligonucleotides
US20230220388A1 (en) * 2020-04-30 2023-07-13 Mpeg La, L.L.C. Multimeric oligonucleotides with divided strands
WO2021231518A1 (en) * 2020-05-13 2021-11-18 The University Of North Carolina At Chapel Hill Nucleic acid ligand conjugates and use thereof for delivery to cells
IL298095A (en) * 2020-05-19 2023-01-01 Mpeg La L L C Orthogonally linked multimeric oligonucleotides
WO2024228030A2 (en) 2023-05-04 2024-11-07 Argonaute RNA Limited Dual silencing

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207381D0 (en) * 1992-04-03 1992-05-13 Ici Plc Synthesis of oligonucleotides
JP2002510644A (ja) 1998-04-03 2002-04-09 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫治療用オリゴヌクレオチドおよびサイトカインを用いる免疫系刺激のための方法および産物
WO2004030634A2 (en) 2002-10-02 2004-04-15 Alnylam Pharmaceuticals Inc. Therapeutic compositions
AU2004220556B2 (en) 2003-03-07 2009-05-07 Alnylam Pharmaceuticals, Inc. Therapeutic compositions
EP1608735A4 (en) 2003-04-03 2008-11-05 Alnylam Pharmaceuticals RNAI CONJUGATES
US8969543B2 (en) 2003-04-03 2015-03-03 Bioneer Corporation SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
CA2521464C (en) 2003-04-09 2013-02-05 Alnylam Pharmaceuticals, Inc. Irna conjugates
CN101273051B (zh) 2003-04-13 2012-04-18 安龙制药公司 聚合寡核苷酸前体药物
CA2522349A1 (en) 2003-04-17 2004-11-04 Alnylam Pharmaceuticals, Inc. Protected monomers
US7851615B2 (en) 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
EP2669377A3 (en) 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modified iRNA agents
WO2006046148A2 (en) 2004-10-25 2006-05-04 Devgen Nv Rna constructs
EP1917357A2 (en) * 2005-08-01 2008-05-07 Purdue Research Foundation Multivalent rna nanoparticles for delivery of active agents to a cell
KR101221589B1 (ko) 2006-04-07 2013-01-15 이데라 파마슈티칼즈, 인코포레이티드 Ｔｌｒ７ 및 ｔｌｒ８에 대한 안정화된 면역 조절성 ｒｎａ〔ｓｉｍｒａ〕 화합물
EP2125855A4 (en) 2007-01-26 2013-03-27 Hope City METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND OTHER DISEASES
US8748405B2 (en) 2007-01-26 2014-06-10 City Of Hope Methods and compositions for the treatment of cancer or other diseases
WO2008109373A1 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting erbb gene expression and uses thereof
WO2008109105A2 (en) 2007-03-06 2008-09-12 Flagship Ventures Methods and compositions for improved therapeutic effects with sirna
JP5737937B2 (ja) 2007-07-09 2015-06-17 イデラ ファーマシューティカルズ インコーポレイテッドＩｄｅｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 安定化免疫調節ｒｎａ（ｓｉｍｒａ）化合物
WO2009126933A2 (en) 2008-04-11 2009-10-15 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
EP2323695B1 (en) 2008-08-19 2018-12-05 Nektar Therapeutics Complexes of small-interfering nucleic acids
US8637194B2 (en) 2008-09-02 2014-01-28 Bio-Nano Power, Llc Bio-nano power cells and their uses
US9394333B2 (en) 2008-12-02 2016-07-19 Wave Life Sciences Japan Method for the synthesis of phosphorus atom modified nucleic acids
WO2010090452A2 (ko) * 2009-02-04 2010-08-12 성균관대학교산학협력단 세포 내 전달능이 증가된 작은 간섭 rna 복합체
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
KR101141544B1 (ko) 2009-03-13 2012-05-03 한국과학기술원 에스아이알엔에이 다중 접합체 및 이의 제조방법
HRP20150566T1 (hr) 2009-08-27 2015-07-17 Idera Pharmaceuticals, Inc. Kompozicija za inhibiciju ekspresije gena i njegova upotreba
KR101678876B1 (ko) 2010-01-15 2016-11-23 한국과학기술원 복합 유전자를 표적하는 ｓｉＲＮＡ 다중 접합체 및 이의 제조방법
SG183374A1 (en) 2010-02-24 2012-09-27 Arrowhead Res Corp Compositions for targeted delivery of sirna
AU2011223820B2 (en) * 2010-03-01 2016-01-14 The Children's Hospital Of Philadelphia Nucleic acids for targeting multiple regions of the HCV genome
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
KR101340290B1 (ko) 2011-09-14 2013-12-11 한국과학기술원 유전자 표적용 ｓｉＲＮＡ 하이드로젤 및 그 제조방법
US9580708B2 (en) 2011-09-14 2017-02-28 Rana Therapeutics, Inc. Multimeric oligonucleotides compounds
EP2895200B1 (en) 2012-09-14 2019-11-06 Translate Bio MA, Inc. Multimeric oligonucleotide compounds
WO2014113802A1 (en) 2013-01-18 2014-07-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. TARGETED SENSITIZATION OF NON-DEL(5q) MALIGNANT CELLS
KR101629681B1 (ko) 2013-06-24 2016-06-14 건국대학교 산학협력단 다중 리간드가 도입된 에스아이알엔에이 접합체
GB201311840D0 (en) * 2013-07-02 2013-08-14 Univ Aberdeen Control of varroa mite infestation
EP2845607A1 (en) 2013-09-09 2015-03-11 University of Vienna Antisense oligonucleotides with improved pharmacokinetic properties
IL314045A (en) 2013-12-12 2024-09-01 Alnylam Pharmaceuticals Inc Complement component irna compositions and methods of use thereof
KR102287532B1 (ko) 2014-01-30 2021-08-11 에프. 호프만-라 로슈 아게 생분해성 컨쥬게이트를 갖는 폴리 올리고머 화합물
WO2016110691A1 (en) * 2015-01-06 2016-07-14 The University Court Of The University Of Aberdeen Enhanced rnai mediated gene regulation
IL316159A (en) * 2015-06-15 2024-12-01 Mpeg La Llc Defined Oligonucleotide Multimers and Methods for Manufacture Thereof
JP7073109B2 (ja) 2015-07-02 2022-05-23 シティ・オブ・ホープ ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法
EP3368671A1 (en) 2015-10-26 2018-09-05 Translate Bio Ma, Inc. Methods and compositions for increasing smn expression
CA3010593C (en) 2016-01-05 2024-02-13 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
JP7016317B2 (ja) 2016-08-08 2022-02-21 浩文 山本 アジュバント組成物
MX2019009347A (es) 2017-02-06 2019-10-07 Mpeg La Llc Oligonucleotidos multimericos con menor eliminacion en el riñon.
CN120330183A (zh) 2017-06-02 2025-07-18 波涛生命科学有限公司 寡核苷酸组合物及其使用方法
WO2019105421A1 (zh) 2017-11-30 2019-06-06 深圳市瀚海基因生物科技有限公司 核苷类似物、制备方法及应用
WO2020180897A1 (en) 2019-03-04 2020-09-10 Mpeg La, L.L.C. Multimeric oligonucleotides with enhanced bioactivity
AU2020319911A1 (en) 2019-07-30 2022-02-24 Mpeg La, L.L.C. Subcutaneous delivery of multimeric oligonucleotides with enhanced bioactivity
IL298095A (en) 2020-05-19 2023-01-01 Mpeg La L L C Orthogonally linked multimeric oligonucleotides

Similar Documents

Publication Publication Date Title
JP2020518552A5 (enExample)
Zhou et al. Aptamers as targeted therapeutics: current potential and challenges
JP2018512155A5 (enExample)
TWI784934B (zh) 抑制lpa之基因表現之組合物及方法
AU2014284836B2 (en) Respiratory disease-related gene specific siRNA, double-helical oligo RNA structure containing siRNA, compositon containing same for preventing or treating respiratory disease
R Kanwar et al. Nucleic acid-based aptamers: applications, development and clinical trials
JP2015519047A5 (enExample)
JP2005517436A5 (enExample)
JP2014518612A5 (enExample)
JP2019503394A5 (enExample)
JP2015518714A5 (enExample)
CN110832077B (zh) 用于抑制α-ENaC表达的RNAi剂及使用方法
JP2007529224A5 (enExample)
JP2016502858A5 (enExample)
JP2015523854A5 (enExample)
JP2013510561A5 (enExample)
JP2025106480A5 (enExample)
JP2020505032A5 (enExample)
EP2950825B1 (en) Functionalized dna dendrimers for gene delivery to cells
JP2014533953A (ja) 治療用ｒｎａスイッチ組成物及び使用方法
JP6847852B2 (ja) 癌治療のためのヒト抗原Ｒ発現のｓｉＲＮＡ阻害
CN114585633A (zh) 寡核苷酸缀合物组合物和使用方法
JP2016539623A5 (enExample)
CN105899663A (zh) 用于基因表达控制的人工模拟miRNA及其用途
EP3419988A1 (en) Novel prna three-way junctions